Novel therapeutics in myeloproliferative neoplasms
Abstract Hyperactive signaling of the Janus-Associated Kinase/Signal Transducers and Activators of Transcription (JAK/STAT) pathway is central to the pathogenesis of Philadelphia-chromosome-negative myeloproliferative neoplasms (MPN), i.e., polycythemia vera (PV), essential thrombocythemia (ET), and...
Auteurs principaux: | Sangeetha Venugopal, John Mascarenhas |
---|---|
Format: | Article |
Langue: | English |
Publié: |
BMC
2020-12-01
|
Collection: | Journal of Hematology & Oncology |
Sujets: | |
Accès en ligne: | https://doi.org/10.1186/s13045-020-00995-y |
Documents similaires
-
Editorial: Biological and clinical implications of the mutational landscape in myeloproliferative neoplasms
par: Giuseppe Gaetano Loscocco, et autres
Publié: (2024-07-01) -
The clinical relevance of broad mutational screening of myeloproliferative neoplasms at diagnosis
par: Helna Pettersson, et autres
Publié: (2023-08-01) -
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
par: Bewersdorf JP, et autres
Publié: (2019-12-01) -
The Role of New Technologies in Myeloproliferative Neoplasms
par: Giuseppe A. Palumbo, et autres
Publié: (2019-04-01) -
Insights from a rare myeloproliferative neoplasm with coexisting BCR‐ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib
par: Li Huo, et autres
Publié: (2023-01-01)